A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
As many as half of obsessive-compulsive disorder (OCD) patients treated with an adequate trial of serotonin reuptake inhibitors (SRIs) fail to fully respond to treatment and continue to exhibit significant symptoms. Many studies have assessed the effectiveness of antipsychotic augmentation in SRI-refractory OCD. In this systematic review, we evaluate the efficacy of antipsychotic augmentation in treatment-refractory OCD. The electronic databases of PubMed, PsychINFO (1967-2005), Embase (1974-2000) and the Cochrane Central Register of Controlled Trials (CENTRAL, as of 2005, Issue 3) were searched for relevant double-blind trials using keywords 'antipsychotic agents' or 'neuroleptics' and 'obsessive-compulsive disorder'. Search results and analysis were limited to double-blind, randomized control trials involving the adult population. The proportion of subjects designated as treatment responders was defined by a greater than 35% reduction in Yale Brown Obsessive-Compulsive Scale (Y-BOCS) rating during the course of augmentation therapy. Nine studies involving 278 participants were included in the analysis. The meta-analysis of these studies demonstrated a significant absolute risk difference (ARD) in favor of antipsychotic augmentation of 0.22 (95% confidence interval (CI): 0.13, 0.31). The subgroup of OCD patients with comorbid tics have a particularly beneficial response to this intervention, ARD=0.43 (95% CI: 0.19, 0.68). There was also evidence suggesting OCD patients should be treated with at least 3 months of maximal-tolerated therapy of an SRI before initiating antipsychotic augmentation owing to the high rate of treatment response to continued SRI monotherapy (25.6%). Antipsychotic augmentation in SRI-refractory OCD is indicated in patients who have been treated for at least 3 months of maximal-tolerated therapy of an SRI. Unfortunately, only one-third of treatment-refractory OCD patients show a meaningful treatment response to antipsychotic augmentation. There is sufficient evidence in the published literature, demonstrating the efficacy of haloperidol and risperidone, and evidence regarding the efficacy of quetiapine and olanzapine is inconclusive. Patients with comorbid tics are likely to have a differential benefit to antipsychotic augmentation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there are some case reports that methylphenidate can worsen OCD symptoms [174] and for some patients antipsychotic medications that reduce dopamine levels are effective [175] (Table 3).”
From Toward a neurocircuit-based taxonomy to guide treatment of obsessive-compulsive disorder (2021) · cites this paper as [175]
In the citing paper
“A meta-analysis of the adult literature examining the use of antipsychotic augmentation in the treatment of OCD showed that the NNT for OCD and tics was 2.3 compared to 5.9 for those with OCD alone.”
From Practice Parameter for the Assessment and Treatment of Children and Adolescents With Tic Disorders (2013) · cites this paper as [139]
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
(1996) · Cited by 6,884
Charbonneau, D. H. (2005) · Europe PMC (PubMed Central) · Cited by 2,041
The Epidemiology of Obsessive-Compulsive Disorder in Five US Communities
Karno, M. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800360042006 · Cited by 1,351
A 40-Year Follow-up of Patients With Obsessive-compulsive Disorder
Skoog, G., & Skoog, I. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.2.121 · Cited by 632
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571
McDougle, C. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950040046006 · Cited by 570
The International Journal of Neuropsychopharmacology
Lerer, B., Frazer, A., Stahl, S., Farde, L., & Lesch, P. (1998) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145798009018 · Cited by 501
The Epidemiology and Differential Diagnosis of Obsessive-Compulsive Disorder
Rasmussen, S. A., & Eisen, J. L. (1992) · Zwangsstörungen / Obsessive-Compulsive Disorders · doi:10.1007/978-3-642-77608-3_1 · Cited by 493
Research works printed but not linked: 2
- Muller C . Vorlaufige Mitteilung zur langen Katamnese der Zwangskranken. Nervenartz 1953; 24: 112–115.
- Rennie TAC . Prognosis in the Psychoneurosis: Benign and Malignant Developments, Current Problems in Psychiatric Diagnosis. New York: Grune & Stratton Inc, 1953.
Cited by
Items 101–200 of 638
Animal models of obsessive-compulsive spectrum disorders
Camilla d'Angelo, L.-S., Eagle, D. M., Grant, J. E., Fineberg, N. A., Robbins, T. W., & Chamberlain, S. R. (2014) · CNS Spectrums · doi:10.1017/s1092852913000564 · Cited by 67
“However, stereotypy was also reduced by mCPP and quinpirole, which detracts from the construct validity of the model, since acute administration of mCPP in the clinic typically exacerbates OCD symptoms,(68,69) and D2 antagonists rather than agonists are used to augment SSRI treatment.(106) Multiple studies have sugges…”
BackgroundResultStriatal indirect pathway mediates exploration via collicular competition
Lee, J., & Sabatini, B. L. (2021) · Nature · doi:10.1038/s41586-021-04055-4 · Cited by 76
Aripiprazole Augmentation in 39 Adolescents With Medication-Resistant Obsessive-Compulsive Disorder
Masi, G., Pfanner, C., Millepiedi, S., & Berloffa, S. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181fab7b1 · Cited by 76
“A systematic meta-analysis included 9 randomized, placebo-controlled studies enrolling 278 patients who received augmentation with various antipsychotics but not aripiprazole and reported that only one third of treated patients resulted responders.(6) According to Bloch and colleagues,(6) evidence supports efficacy of…”
BackgroundMasi, G., Pfanner, C., & Brovedani, P. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.04.003 · Cited by 77
“Adjunctive medications are frequently used in ordinary clinical settings as augmenting strategies in adult OCD for unsatisfactory response to SSRIs monotherapy (Bloch et al., 2006). Maina et al. (2008) randomized 50 adult patients with OCD non responding to a 16-week SSRI trial to risperidone vs.”
BackgroundInfluentialA cytokine study in children and adolescents with Tourette's disorder
Gabbay, V., Coffey, B. J., Guttman, L. E., Gottlieb, L., Katz, Y., Babb, J. S., Hamamoto, M. M., & Gonzalez, C. J. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.05.001 · Cited by 78
“, 2005), and phenomenologically by clinical presentation and pharmacological response (Bloch et al., 2006; Coffey et al., 1998; Kwak et al., 2003).”
BackgroundDiniz, J. B., Shavitt, R. G., Fossaluza, V., Koran, L., Pereira, C. A. D. B., & Miguel, E. C. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182367aee · Cited by 73
“The use of antipsychotics combined with SRIs is listed as a second-line treatment strategy in international treatment guidelines(10,11) and is the only such strategy that has proven effective according to meta-analyses.(12,13) The addition of an antipsychotic to the treatment regimen has been associated with meaningfu…”
BackgroundMetabolic syndrome and obsessive–compulsive disorder: a naturalistic Italian study
Albert, U., Aguglia, A., Chiarle, A., Bogetto, F., & Maina, G. (2012) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2012.10.004 · Cited by 79
“No study, to our knowledge, investigated the prevalence of MetS among subjects with OCD, despite the fact that antipsychotic augmentation of SRI is one of the most effective and studied strategies in resistant OCD [36-38].”
BackgroundPessina, E., Albert, U., Bogetto, F., & Maina, G. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832e9b91 · Cited by 71
“…and larger trials, as differences might exist between different antipsychotics (Bloch et al., 2006; Ipser et al., 2006; Skapinakis et al., 2007): Bloch et al. (2006), for example, concluded that there is sufficient evidence showing the efficacy of haloperidol and risperidone, whereas the…”
BackgroundTrends in Psychiatry and Psychotherapy
(2020) · Trends in Psychiatry and Psychotherapy · doi:10.47626/2237-6089 · Cited by 70
The anterior limb of the internal capsule: Anatomy, function, and dysfunction
Mithani, K., Davison, B., Meng, Y., & Lipsman, N. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112588 · Cited by 74
Senço, N. M., Huang, Y., D’Urso, G., Parra, L. C., Bikson, M., Mantovani, A., Shavitt, R. G., Hoexter, M. Q., Miguel, E. C., & Brunoni, A. R. (2015) · Expert Review of Medical Devices · doi:10.1586/17434440.2015.1037832 · Cited by 67
“Overall, 30% of OCD patients are refractory to any conventional first or second line treatment [9].”
BackgroundTreatment-refractory Tourette Syndrome
Kious, B. M., Shahed, J. J., & Shprecher, D. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.02.003 · Cited by 71
“Not surprisingly, greater tic severity in childhood predicts tic persistence in adulthood (Bloch et al., 2006b), as do early fine motor deficits (Bloch et al., 2006c).”
BackgroundTreatment of Pediatric Obsessive-Compulsive Disorder: A Review
Mancuso, E., Faro, A. L., Joshi, G., & GELLER, D. A. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0040 · Cited by 74
“High-quality RCTsusing atypicals have been done in adults with OCD and are summarized in a comprehensive meta-analysis by Bloch et al. (2006), who found a NNT of 4.5, with risperidone and haloperidol showing significant advantage over placebo and even better response for those with co-morbid tic…”
InfluentialEmerging treatments for Tourette’s disorder
Bloch, M. H. (2008) · Current Psychiatry Reports · doi:10.1007/s11920-008-0052-z · Cited by 68
Self-citationTourette disorder and other tic disorders
Deeb, W., Malaty, I. A., & Mathews, C. A. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64012-3.00008-3 · Cited by 73
Pallanti, S., Bernardi, S., Antonini, S., Singh, N., & Hollander, E. (2009) · CNS Drugs · doi:10.2165/11530240-000000000-00000 · Cited by 74
Neurotrophic factors in obsessive-compulsive disorder
Fontenelle, L. F., Barbosa, I. G., Luna, J. V., Rocha, N. P., de Miranda, A. S., & Teixeira, A. L. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.03.034 · Cited by 73
“For instance, patients with OCD who respond partially to 5HT reuptake inhibitors (SRI) benefit from D2 blocking drugs (Bloch et al., 2006), dopaminergic drugs lead to OCD-like behaviors in animals (Eilam and Szechtman, 2005) and humans (Crum and Anthony, 1993; O'Sullivan et al., 2010), and…”
Schizo-obsessive spectrum disorders: an update
Scotti-Muzzi, E., & Saide, O. L. (2017) · CNS Spectrums · doi:10.1017/s1092852916000390 · Cited by 65
“The prevalence rate of schizophrenia in the general population is nearly 1%,(1) whereas the corresponding rate of obsessive compulsive disorder (OCD) is as high at 2%–3%.(2) Instances of the co-occurrence of psychotic and obsessive–compulsive symptoms (OCS) have been noted since the 19th century with low prevalence ra…”
BackgroundA 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder
Stein, D. J., Koen, N., Fineberg, N., Fontenelle, L. F., Matsunaga, H., Osser, D., & Simpson, H. B. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0268-9 · Cited by 65
Van Ameringen, M., Simpson, W., Patterson, B., Dell’Osso, B., Fineberg, N., Hollander, E., Hranov, L., Hranov, G., Lochner, C., Karamustafalioglu, O., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113517955 · Cited by 65
“The results of these reviews revealed that augmentation with medication (in general) was better than adding placebo (Bloch et al., 2006; Ipser et al., 2006; Skapinakis et al., 2007), and that although effective and significantly superior to placebo, augmentation with antipsychotic agents produced a…”
BackgroundResultInfluentialGeller, D. A., March, J., & AACAP Committee on Quality Issues (CQI) (2012) · Focus · doi:10.1176/appi.focus.10.3.360 · Cited by 63
Selvi, Y., Atli, A., Aydin, A., Besiroglu, L., Ozdemir, P., & Ozdemir, O. (2011) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1169 · Cited by 64
“In an adequate trial of an SRI, a less than 25–35% decrease in the Yale-Brown ObsessiveCompulsive Scale (Y-BOCS) score in patients with at least moderate obsessive compulsive symptom severity is usually considered partial response or non-response (Albert et al., 2002; Bloch et al., 2006; Denys, 2006; Pallanti and Quer…”
BackgroundInfluentialBridging the Great Divide: What Can Neurology Learn From Psychiatry?
Perez, D. L., Keshavan, M. S., Scharf, J. M., Boes, A. D., & Price, B. H. (2018) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.17100200 · Cited by 69
Current and emerging brain applications of MR-guided focused ultrasound
Meng, Y., Suppiah, S., Mithani, K., Solomon, B., Schwartz, M. L., & Lipsman, N. (2017) · Journal of Therapeutic Ultrasound · doi:10.1186/s40349-017-0105-z · Cited by 66
“However, despite optimal care, up to 30 to 40% of patients remain significantly disabled [49, 50].”
BackgroundGlutamatergic agents for OCD and related disorders
Pittenger, C. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0051-8 · Cited by 62
“Evidence-based options after these first-line treatments are exhausted are, however, limited [7, 9, 10].”
BackgroundRodriguez, C. I., Kegeles, L. S., Levinson, A., Ogden, R. T., Mao, X., Milak, M. S., Vermes, D., Xie, S., Hunter, L., Flood, P., et al. (2015) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2015.06.001 · Cited by 59
“Moreover, the only evidence-based medication strategy for augmenting SRIs in OCD is the addition of antipsychotics; however, this is effective in only one third of patients (Bloch et al., 2006).”
BackgroundPharmacological Treatment of Obsessive-Compulsive Disorder
Simpson, H. B. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_12 · Cited by 59
Math, S. B., & Janardhan Reddy, Y. C. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01356.x · Cited by 59
Management of Schizophrenia with Obsessive-Compulsive Features
Hwang, M. Y., Kim, S., Yum, S. Y., & Opler, L. A. (2009) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.08.002 · Cited by 61
“If the OCS seem to have started or worsened with clozapine treatment, clinicians should consider switching to another antipsychotic after weighing the benefits derived from clozapine against the morbidity caused by an increase in OCS.”
ResultInfluentialKopřivová, J., Congedo, M., Raszka, M., Praško, J., Brunovský, M., & Horáček, J. (2013) · Neuropsychobiology · doi:10.1159/000347087 · Cited by 53
Diniz, J., Shavitt, R., Pereira, C., Hounie, A., Pimentel, I., Koran, L., Dainesi, S., & Miguel, E. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881108099423 · Cited by 57
Emamzadehfard, S., Kamaloo, A., Paydary, K., Ahmadipour, A., Zeinoddini, A., Ghaleiha, A., Mohammadinejad, P., Zeinoddini, A., & Akhondzadeh, S. (2016) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12394 · Cited by 55
The Pediatric Obsessive-Compulsive Disorder Treatment Study II: rationale, design and methods
Freeman, J. B., Choate-Summers, M. L., Garcia, A. M., Moore, P. S., Sapyta, J. J., Khanna, M. S., March, J. S., Foa, E. B., & Franklin, M. E. (2009) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-3-4 · Cited by 54
Ducasse, D., Boyer, L., Michel, P., Loundou, A., Macgregor, A., Micoulaud‐Franchi, J., Courtet, P., Abbar, M., Leboyer, M., & Fond, G. B. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3516-3 · Cited by 63
Zink, M. (2014) · Advances in Medicine · doi:10.1155/2014/317980 · Cited by 61
Pittenger, C., Adams, T. G., Gallezot, J.-D., Crowley, M. J., Nabulsi, N., Ropchan, J., Gao, H., Kichuk, S. A., Simpson, R., Billingslea, E., et al. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.02.021 · Cited by 58
Self-citationObsessive-Compulsive Spectrum Disorders: A Review of the Evidence-Based Treatments
Ravindran, A. V., da Silva, T. L., Ravindran, L. N., Richter, M. A., & Rector, N. A. (2009) · The Canadian Journal of Psychiatry · doi:10.1177/070674370905400507 · Cited by 58
“Augmentation with atypical antipsychotics is now the most frequently used therapeutic strategy for treatment of refractory OCD.(165,166) Patients with comorbid tic disorders seem to respond particularly well to this augmentation.”
BackgroundInfluentialMorein-Zamir, S., Craig, K. J., Ersche, K. D., Abbott, S., Muller, U., Fineberg, N. A., Bullmore, E. T., Sahakian, B. J., & Robbins, T. W. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1963-z · Cited by 54
“Atypical neuroleptics can augment the effectiveness of selective serotonin reuptake inhibitors (SSRIs) in OCD, particularly in those patients refractory to SSRIs alone (Bloch et al. 2006; Denys et al. 2004a; McDougle et al. 2000; Metin et al. 2003).”
BackgroundPharmacotherapeutic Strategies and New Targets in OCD
Pittenger, C. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_204 · Cited by 59
Recent Advances in the Understanding and Treatment of Anxiety Disorders
Shearer, S. L. (2007) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2007.05.002 · Cited by 62
de Avila, R. C. S., do Nascimento, L. G., Porto, R. L. D. M., Fontenelle, L., Filho, E. C. M., Brakoulias, V., & Ferrão, Y. A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00413 · Cited by 50
Storch, E. A., Lehmkuhl, H., Geffken, G. R., Touchton, A., & Murphy, T. K. (2008) · Depression and Anxiety · doi:10.1002/da.20303 · Cited by 53
“Studies investigating atypical antipsychotic augmentation among adults have shown a modest response rate ranging from 33 to 50% [Bloch et al., 2006].”
BackgroundMack, H., Fullana, M. A., Russell, A., Mataix‐Cols, D., Nakatani, E., & Heyman, I. (2010) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048674.2010.515561 · Cited by 58
Lamothe, H., Schreiweis, C., Mondragón-González, S. L., Rebbah, S., Lavielle, O., Mallet, L., & Burguière, E. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02323-7 · Cited by 53
“The hypothesis of generally compromised cortico-dorsostriatal circuitry mediating RBs is also in line with the observed strong comorbidity of tic- and compulsive-like symptoms in patients with Tourette syndrome or OCD [3, 49–52] and this comorbidity is decisive for successful treatment [49, 50, 53].”
BackgroundResultAssessing the validity of current mouse genetic models of obsessive-compulsive disorder
Wang, L., Simpson, H. B., & Dulawa, S. C. (2009) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32832a80ad · Cited by 50
“A systematic review of antipsychotic augmentation (Bloch et al., 2006), which combined nine double-blind, randomized controlled clinical trials involving 278 patients, showed that approximately one-third of OCD patients benefit from antipsychotic augmentation, with strong evidence supporting the…”
BackgroundInfluentialSchirmbeck, F., Rausch, F., Englisch, S., Eifler, S., Esslinger, C., Meyer-Lindenberg, A., & Zink, M. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112463470 · Cited by 49
The Medical Treatment of Obsessive-Compulsive Disorder and Anxiety
Bandelow, B. (2008) · CNS Spectrums · doi:10.1017/s1092852900026924 · Cited by 49
Predictors of response to serotonin reuptake inhibitors in obsessive-compulsive disorder
Hazari, N., Narayanaswamy, J. C., & Arumugham, S. S. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1199960 · Cited by 52
“It has been seen that only 40–60% of the patients respond adequately to a trial of SRIs [5,6] and more than 30–40% of the patients fail to respond to a subsequent trial with SRIs [7].”
BackgroundHeidari, M., Zarei, M., Hosseini, S. M. R., Taghvaei, R., Maleki, H., Tabrizi, M., Fallah, J., & Akhondzadeh, S. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000043 · Cited by 48
“Moreover, despite the fact that serotonin reuptake inhibitors (SRIs) are the mainstay of treatment and are used widely, almost 40–60% of patients fail to respond to initial treatment with these agents (Erzegovesi et al., 2001; Hollander et al., 2002; Bloch et al., 2006).”
BackgroundSystematic review of co-occurring OCD and TD: Evidence for a tic-related OCD subtype?
Kloft, L., Steinel, T., & Kathmann, N. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.09.021 · Cited by 47
Neuroimaging of psychotherapy for obsessive–compulsive disorder: A systematic review
Thorsen, A. L., van den Heuvel, O. A., Hansen, B., & Kvale, G. (2015) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2015.05.004 · Cited by 46
“…cognitive-behavioral therapy (CBT) with exposure and response prevention and pharmacological treatment by selective serotonin reuptake inhibitors (SSRIs), with eventual adjuvant atypical antipsychotic medication in treatment-resistant cases (Abramowitz, 1997; Bloch et al., 2006; Gava et al., 2007).”
BackgroundPampaloni, I., Sivakumaran, T., Hawley, C., Al Allaq, A., Farrow, J., Nelson, S., & Fineberg, N. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109104850 · Cited by 47
Marazziti, D., Golia, F., Consoli, G., Presta, S., Pfanner, C., Carlini, M., Mungai, F., & Dell'Osso, M. C. (2008) · CNS Spectrums · doi:10.1017/s1092852900014024 · Cited by 45
Obsessive–compulsive disorders
Thomsen, P. H. (2012) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-012-0357-7 · Cited by 48
“Although large randomised controlled trials are still lacking, the best described drugs for augmentation are risperidone and abilify [36, 37].”
BackgroundEpidemiology and Management of Anxiety in Patients with Bipolar Disorder
Kauer‐Sant’Anna, M., Kapczinski, F. P., & Vieta, E. (2009) · CNS Drugs · doi:10.2165/11310850-000000000-00000 · Cited by 46
Kim, S., Shin, I., Kim, J., Yang, S., Hwang, M. Y., & Yoon, J. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318172755a · Cited by 47
Antipsychotic Use in Children and Adolescents: A 1-Year Follow-Up Study
Baeza, I., de la Serna, E., Calvo, R. M., Morer, Á., Merchán‐Naranjo, J., Tapia, C., Martínez‐Cantarero, C., Andrés, P., Alda, J. A., Sánchez, B., et al. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000190 · Cited by 47
“Unauthorized reproduction of this article is prohibited. tendency to increase weight and improve depressive and obsessive symptoms compared with FGA.33,34 However, a recent meta-analysis failed to demonstrate their efficacy for increasing body weight or improving psychopathology in patients with anorexia nervosa.35 Si…”
ResultZhou, D., Zhou, X., Li, Y., Zhang, K.-F., Lv, Z., Chen, X., Wan, L.-Y., Wang, W., Wang, G.-M., Li, D., et al. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.12.009 · Cited by 48
Polypharmacy with antidepressants in children and adolescents
Díaz‐Caneja, C. M., Espliego, A., Parellada, M., Arango, C., & Moreno, C. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001265 · Cited by 46
Lawford‐Smith, H. (2015) · Journal of Social Ontology · doi:10.1515/jso-2015-0008 · Cited by 59
Pallanti, S., Bernardi, S., Antonini, S., Singh, N., & Hollander, E. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.003 · Cited by 42
“However, given the side-effect profile of antipsychotics, and since only one third of treatment refractory OCD patients show a meaningful treatment response to antipsychotic augmentation (Bloch et al., 2006), the search for other pharmacological strategies has generated considerable interest.”
InfluentialThe Role of Serotonin in Orbitofrontal Function and Obsessive-Compulsive Disorder
Maia, T. V., & Cano-Colino, M. (2015) · Clinical Psychological Science · doi:10.1177/2167702614566809 · Cited by 42
“Second-generation antipsychotics are the most common pharmacological augmentation strategy for patients who do not respond to SRI monotherapy (Bloch et al., 2006; Dold, Aigner, Lanzenberger, & Kasper, 2013).”
BackgroundEgashira, N., Okuno, R., Matsushita, M., Abe, M., Mishima, K., Iwasaki, K., Nishimura, R., Oishi, R., & Fujiwara, M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.100 · Cited by 46
Wood, J., LaPalombara, Z., & Ahmari, S. E. (2018) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2017.0023 · Cited by 41
Glutamate Modulators in the Treatment of Obsessive-Compulsive Disorder
Pittenger, C. (2015) · Psychiatric Annals · doi:10.3928/00485713-20150602-06 · Cited by 37
The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap
Szechtman, H., Harvey, B. H., Woody, E. Z., & Hoffman, K. L. (2019) · Pharmacological Reviews · doi:10.1124/pr.119.017772 · Cited by 41
“Bloch et al. (2006) published the first meta-analysis of double-blind, randomized controlled clinical trials evaluating antipsychotic agents as an augmentation strategy in adults with treatment-refractory OCD; “treatment-refractory” was defined by the lack of response to at least 2 months of…”
BackgroundSalomoni, G., Grassi, M., Mosini, P., Riva, P., Cavedini, P., & Bellodi, L. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181aba68f · Cited by 46
“39 Comparing with literature, 7 the lower rate of responders in our sample may be due to the higher response cutoff score; in fact, we chose 40% Y-BOCS reduction of baseline symptoms severity instead of its usual 35% total score reduction with the aim to clearly define a true treatment response…”
An update on the pharmacological treatment of obsessive-compulsive disorder
Fontenelle, L. F., Nascimento, A. L., Mendlowicz, M. V., Shavitt, R. G., & Versiani, M. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.5.563 · Cited by 42
“Selected articles included not only treatment trials, but also key meta-analytical [12-20], systematic [5,6,21] and narrative reviews [22-24], as well as treatment guidelines and recommendations from several different professional societies, including the Canadian Psychiatric Association [25], the British Association…”
BackgroundObsessive-Compulsive Spectrum Disorders:Cross-national and Ethnic Issues
Matsunaga, H., & Seedat, S. (2007) · CNS Spectrums · doi:10.1017/s1092852900021180 · Cited by 40
Management of Obsessive-Compulsive Disorder
Seibell, P. J., & Hollander, E. (2014) · F1000Prime Reports · doi:10.12703/p6-68 · Cited by 46
Animal models of obsessive compulsive disorder: recent findings and future directions
Hoffman, K. L. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.577772 · Cited by 40
Different Views of Anxiety Disorders
Selek, S. (2011) · InTech eBooks · doi:10.5772/1022 · Cited by 39
Circadian rhythms in obsessive–compulsive disorder
Lange, K. W., Lange, K. M., Hauser, J., Tucha, L., & Tucha, O. M. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0805-z · Cited by 42
“Forty to 60 % of patients with OCD, however, do not respond satisfactorily to SRIs (Bloch et al. 2006; da Rocha and Correa 2007; Pallanti et al. 2002).”
BackgroundAfshar, H., Akuchekian, S., Mahaky, B., & Zarean, E. (2014) · PubMed Central · Cited by 52
Praško, J. P., Raszka, M., Adamcová, K., Grambal, A., Kopřivová, J., Kudrnovská, H., Látalová, K., & Vyskocilova, J. (2009) · PubMed · Cited by 42
Moritz, S., Claussen, M., Hauschildt, M., & Kellner, M. B. (2014) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000156 · Cited by 40
“…effects of antipsychotic drugs (Miyamoto et al., 2012), their low acceptance in OCD (Voderholzer et al., submitted), and equivocal findings on the efficacy of antipsychotics in OCD (Bloch et al., 2006; Kellner, 2010; Simpson et al., 2013), nonpharmacological options need to be considered as well.”
ResultSequential Allocation to Balance Prognostic Factors in a Psychiatric Clinical Trial
Fossaluza, V., Diniz, J. B., de Bragança Pereira, B., Miguel, E. C., & de Bragança Pereira, C. A. (2009) · Clinics · doi:10.1590/s1807-59322009000600005 · Cited by 38
Obsessive–compulsive symptoms in schizophrenia: a review
Grover, S., Sahoo, S., & Surendran, I. (2018) · Acta Neuropsychiatrica · doi:10.1017/neu.2018.27 · Cited by 39
Obsessive-Compulsive Disorders
Mathews, C. (2021) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001011 · Cited by 43
Treatment-refractory obsessive compulsive disorder
Atmaca, M. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.12.004 · Cited by 44
“In a meta- AC C EP TE D M AN U SC R IP T tolerability between different doses of SSRIs in OCD patients and suggested that higher doses of SSRIs were related to greater efficacy.”
BackgroundMethodInfluentialNajafi, K., Fakour, Y., Zarrabi, H., Heidarzadeh, A., Khalkhali, M., Yeganeh, T., فرهی, ح., Rostamkhani, M., Najafi, T., Shabafroz, S., et al. (2017) · Indian Journal of Psychological Medicine · doi:10.4103/ijpsym.ijpsym_388_16 · Cited by 39
“However, drugs’ side effects and residual symptoms of OCD at middle level will decrease patients’ tendency in taking them.[6] The other medical ways such as electroconvulsive therapy, psychosurgery, brain deep stimulation, and vagus nerve stimulation have little efficacy and can cause memory dysfunction, anesthesia co…”
BackgroundTreatment of Obsessive-Compulsive Disorder
Stein, D. J., Ipser, J. C., Baldwin, D. S., & Bandelow, B. (2007) · CNS Spectrums · doi:10.1017/s1092852900002480 · Cited by 38
Predictors of early adulthood quality of life in children with obsessive–compulsive disorder
Palermo, S. D., Bloch, M. H., Craiglow, B. G., Landeros‐Weisenberger, A., Dombrowski, P. A., Panza, K. E., Smith, M. E., Peterson, B. S., & Leckman, J. F. (2010) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-010-0194-2 · Cited by 43
“Tics in OCD patients have been previously associated with a differential response to pharmacological interventions for OCD such as sertraline treatment and antipsychotic augmentation [16, 17].”
BackgroundSelf-citationObsessive–compulsive Disorder: Diagnostic and Treatment Issues
Stein, D. J., Denys, D. A. J. P., Gloster, A. T., Hollander, E., Leckman, J. F., Rauch, S. L., & Phillips, K. A. (2009) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.05.007 · Cited by 45
Self-citationKim, D., Ryba, N., Kalabalik, J., & Westrich, L. (2018) · Drugs in R&D · doi:10.1007/s40268-018-0246-8 · Cited by 38
“efficacious in one third of the patients [116].”
BackgroundZhou, D.-D., Zhou, X.-X., Lv, Z., Chen, X.-R., Wang, W., Wang, G.-M., Liu, C., Li, D.-Q., & Kuang, L. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.01.014 · Cited by 37
Batistuzzo, M. C., Hoexter, M. Q., Taub, A., Gentil, A. F., Cesar, R. C., Joaquim, M. A., D′Alcante, C. C., McLaughlin, N. C. R., Canteras, M. M., Shavitt, R. G., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.33 · Cited by 40
Einoch, R., Weinreb, O., Mandiuk, N., Youdim, M. B. H., Bilker, W. B., & Silver, H. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.03.005 · Cited by 39
Treatment strategies for obsessive-compulsive disorder
Marazziti, D., & Consoli, G. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903446948 · Cited by 45
“In conclusion, the addition of antipsychotics to ongoing serotonergic treatment represents one of the most extensively studied and well-documented strategies to overcome resistance in OCD, and it is noteworthy that different meta-analyses support its validity [98,99].”
BackgroundSimpson, H. B., Foa, E. B., Liebowitz, M. R., Ledley, D. R., Huppert, J. D., Cahill, S., Vermes, D., Schmidt, A. B., Hembree, E., Franklin, M., et al. (2010) · Focus · doi:10.1176/foc.8.4.foc614 · Cited by 35
Khalkhali, M., Aram, S., Zarrabi, H., Kafie, M., & Heidarzadeh, A. (2016) · PubMed Central · Cited by 46
The Endocannabinoid System: A New Treatment Target for Obsessive Compulsive Disorder?
Kayser, R. R., Snorrason, I., Haney, M., Lee, F. S., & Simpson, H. B. (2019) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0049 · Cited by 35
Kim, S.-W., Shin, I.-S., Kim, J.-M., Youn, T., Yang, S.-J., Hwang, M. Y., & Yoon, J.-S. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e318184fafd · Cited by 36
“There is sufficient evidence demonstrating the efficacy of haloperidol in treatmentrefractory OCD.(4) In a comparative study between risperidone and haloperidol on refractory OCD, haloperidol demonstrated a stronger and significant reduction in the total Yale-Brown Obsessive Compulsive Scale (YBOCS) score than a place…”
BackgroundInfluentialCase Series: Transformation Obsession in Young People With Obsessive-Compulsive Disorder (OCD)
Volz, C., & Heyman, I. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3180465a2e · Cited by 39
“There is some evidence that antipsychotics can augment the effectiveness of SSRI medication in the treatment of OCD, but this maneuver is usually reserved for treatment resistance, not initiated early in the course of treatment (Bloch et al., 2006).”
BackgroundArabzadeh, S., Shahhossenie, M., Mesgarpour, B., Rezaei, F., Shalbafan, M., Ghiasi, Z., & Akhondzadeh, S. (2017) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2584 · Cited by 39
Krebs, G., & Heyman, I. (2009) · Child and Adolescent Mental Health · doi:10.1111/j.1475-3588.2009.00548.x · Cited by 42
Shalbafan, M., Malekpour, F., Najafabadi, B. T., Ghamari, K., Dastgheib, S. A., Mowla, A., Shirazi, E., Ardebili, M. E., Ghazizadeh‐Hashemi, M., & Akhondzadeh, S. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119878177 · Cited by 37
“This hyperdopaminergic state and the similarity with schizophrenia could be a reason why antipsychotic drugs have shown positive additional effects when augmented with SSRIs toward the treatment of OCD (Bloch et al., 2006; Dold et al., 2013; McDougle et al., 1994; Veale et al., 2014).”
BackgroundFoa, E. B., Simpson, H. B., Rosenfield, D., Liebowitz, M. R., Cahill, S. P., Huppert, J. D., Bender Jr, J., McLean, C. P., Maher, M. J., Campeas, R., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09044 · Cited by 34
Cigarette smoking in obsessive-compulsive disorder and unaffected parents of OCD patients
Abramovitch, A., Pizzagalli, D. A., GELLER, D. A., Reuman, L., & Wilhelm, S. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2013.12.003 · Cited by 36
“Dopamine antagonists (neuroleptics) have been demonstrated as efficacious therapeutic agents when used to augment SRIs in OCD [10].”
BackgroundTrichotillomania is more related to Tourette disorder than to obsessive-compulsive disorder
Lamothe, H., Baleyte, J., Mallet, L., & Pélissolo, A. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-0471 · Cited by 37
Metadata
- Authors
- Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F.
- Affiliations
- Yale University (US)
- Connecticut Mental Health Center (US)
- Corresponding author
- Bloch, M H
- Venue
- Molecular Psychiatry
- Published
- 2006-04-04
- Volume
- 11
- Issue
- 7
- Pages
- 622-632
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2100202859
- Cited by
- 635
- References
- 50
- Citations by year
- 2026: 24 · 2025: 21 · 2024: 22 · 2023: 14 · 2022: 18 · 2021: 25 · 2020: 21 · 2019: 29 · 2018: 34 · 2017: 37 · 2016: 30 · 2015: 53 · 2014: 48 · 2013: 39 · 2012: 39
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Update notices
- erratum (2006-07-26)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Tourette Association of America
- National Institutes of Health
- U.S. Public Health Service
- National Institute of Mental Health
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- obsessive-compulsive disorder, treatment-refractory OCD, antipsychotic augmentation, serotonin reuptake inhibitors, haloperidol, risperidone, quetiapine, olanzapine, treatment response, Yale-Brown Obsessive Compulsive Scale
- MeSH terms
- Quetiapine Fumarate, Olanzapine, Adult, Aged, Basal Ganglia Diseases, Benzodiazepines, Depressive Disorder, Dibenzothiazepines, Double-Blind Method, Drug Resistance, Drug Therapy, Combination, Haloperidol, Humans, Middle Aged, Obsessive-Compulsive Disorder, Patient Dropouts, Tic Disorders, Antipsychotic Agents, Comorbidity, Randomized Controlled Trials as Topic, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.